Peptide-Mediated Nanocarriers for Targeted Drug Delivery: Developments and Strategies

Yubo Wang,Lu Zhang,Chen Liu,Yiming Luo,Dengyue Chen

DOI: https://doi.org/10.3390/pharmaceutics16020240

IF: 6.525

2024-02-07

Pharmaceutics

Abstract:Effective drug delivery is essential for cancer treatment. Drug delivery systems, which can be tailored to targeted transport and integrated tumor therapy, are vital in improving the efficiency of cancer treatment. Peptides play a significant role in various biological and physiological functions and offer high design flexibility, excellent biocompatibility, adjustable morphology, and biodegradability, making them promising candidates for drug delivery. This paper reviews peptide-mediated drug delivery systems, focusing on self-assembled peptides and peptide–drug conjugates. It discusses the mechanisms and structural control of self-assembled peptides, the varieties and roles of peptide–drug conjugates, and strategies to augment peptide stability. The review concludes by addressing challenges and future directions.

pharmacology & pharmacy

What problem does this paper attempt to address?

### Problems Addressed by the Paper

This paper aims to explore the application and development strategies of peptide-mediated nanocarriers in targeted drug delivery. Specifically, the article focuses on the following aspects:

1. **Improving Drug Delivery Efficiency**: Peptide-mediated drug delivery systems can actively recognize tumor-specific receptors, thereby achieving better tumor targeting, enhanced retention time, and increased tumor cell uptake. These systems have significant advantages over free drugs or passive targeting systems.

2. **Overcoming Multidrug Resistance**: Peptide-mediated delivery systems exhibit a stronger ability to overcome tumor multidrug resistance (MDR).

3. **Reducing Immunogenicity and Cost**: Compared to monoclonal antibody-mediated systems, peptide-mediated systems have simple preparation methods, low immunogenicity, suitable stability, and ease of delivery.

However, despite the numerous advantages of peptide-mediated nanodelivery systems, they still face some challenges. For instance, they may be captured by the reticuloendothelial system, leading to widespread distribution in the liver and spleen, which affects their functionality. The variability of tumor tissue receptors and the presence of peptide-degrading enzymes in vivo can also impact the efficiency and targeting performance of the systems. Therefore, further research is needed to enhance the targeting efficiency of peptide-mediated tumor-targeting nanodelivery systems.

In summary, this paper reviews the research progress of self-assembling peptides and peptide-drug conjugates and discusses strategies to enhance peptide stability, aiming to provide new directions and insights for the development of peptide-mediated drug delivery systems.